Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Small Molecule Inhibition of MAGE-A3 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Anna Huo Chang Mei, Husnu Kaniskan, Kwang-su Park, Jian Jin, Roman Osman, Hearn Jay Cho

Blood (2023) 142 (Supplement 1): 6568.

https://doi.org/10.1182/blood-2023-179520

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Lucia Y Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2023-190368

Published: 2023

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Santiago Thibaud, Jerrel Catlett, Saoirse Bodnar, MD Babu Mia, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Sundar Jagannath, Shambavi Richard, Samir Parekh

Blood (2023) 142 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2023-190772

Published: 2023

Journal Articles

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Darren Denjay Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Hearn Jay Cho, Joshua Richter, Larysa J Sanchez, Santiago Thibaud, Cesar Rodriguez, Shambavi Richard

Blood (2023) 142 (Supplement 1): 92.

https://doi.org/10.1182/blood-2023-188310

Published: 2023

Journal Articles

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Blood (2023) 142 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2023-184409

Published: 2023

Journal Articles

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

Selma Bekri, Simone Katz, Geoffrey Kelly, Travis Dawson, Darwin D'Souza, Michael Mason, Alexandre Alloy, Shameek Biswas, Seunghee Kim-Schulze, Sacha Gnjatic, Samir Parekh, Sundar Jagannath, Alessandro Lagana, Hearn Jay Cho

Blood (2023) 142 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2023-189882

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, Zachry Soens, Scott Newman, Rong Chen, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, David T. Melnekoff, Shambavi Richard, Joshua Richter, Larysa Sanchez, Kuan-lin Huang, Alessandro Lagana, Samir Parekh, Kenan Onel

Blood (2021) 138 (Supplement 1): 399.

https://doi.org/10.1182/blood-2021-151495

Published: 2021

Journal Articles

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 457.

https://doi.org/10.1182/blood-2021-150522

Published: 2021

Journal Articles

Interim Analysis of Mmrf Curecloud Research Initiative Identifies High Prevalence and Patterns of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations in a Real World Myeloma Cohort

Reyka G Jayasinghe, Annette S. Kim, Teni Dowdell, Carrie Cibulskis, Jennifer Yesil, Debanjana Chatterjee, Michele Likens, Shaadi Mehr, Cartik Saravanamuthu, Jean-Baptiste Alberge, Emily Lapinskas, Steven E Labkoff, Keith L Ligon, Hearn Jay Cho, Irene M. Ghobrial, Daniel Auclair

Blood (2021) 138 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2021-148782

Published: 2021

Journal Articles

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

David G. Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, Javier Diaz-Mejia3, Ping Luo, Yong Zhang, Yuexin Xu, Edus H. Warren, Eric L Smith, Hearn Jay Cho, Alexander Lesokhin, Benjamin Diamond, Dickran Kazandjian, Trevor J. Pugh, Damian J. Green, Sacha Gnjatic, Ola Landgren

Blood (2021) 138 (Supplement 1): 329.

https://doi.org/10.1182/blood-2021-154506

Published: 2021

Journal Articles

Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study

William Pilcher, Beena E Thomas, Swati S Bhasin, Reyka G Jayasinghe, Adeeb H Rahman, Seunghee Kim-Schulze, Edgar Gonzalez-Kozlova, Taxiarchis Kourelis, Madhav V Dhodapkar, Ravi Vij, Shaji Kumar, Shaadi Mehr, Mark Hamilton, Hearn Jay Cho, Daniel Auclair, David Avigan, Sacha Gnjatic, Li Ding, Manoj Bhasin

Blood (2021) 138 (Supplement 1): 401.

https://doi.org/10.1182/blood-2021-153863

Published: 2021

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

Journal Articles

Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Blood (2021) 138 (Supplement 1): 2691.

https://doi.org/10.1182/blood-2021-154081

Published: 2021

Journal Articles

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Stefania Stefania Mancia, Annamaria Farrell, Karen Louw, Erika Florendo, Elizabeth Aronson, Kiah Purcell, Donna D Catamero, Juliet Escalon, Joanne Thomas, Annel Aponte, Angela Lamb, Diana Kirke, Aimee Lucas, Sundar Jagannath, Hearn Jay Cho, Samir Parekh, Joshua Richter, Larysa Sanchez, Ajai Chari

Blood (2021) 138 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2021-153817

Published: 2021

NARROW

Small Molecule Inhibition of MAGE-A3 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Pathogenic Germline Variants in Multiple Myeloma

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Interim Analysis of Mmrf Curecloud Research Initiative Identifies High Prevalence and Patterns of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations in a Real World Myeloma Cohort

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only